← All trials
NCT06045806
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 16, 2023
- Primary completion
- Mar 27, 2031
- Completion date
- Jul 4, 2032
- First posted
- Sep 21, 2023
- Last posted
- Dec 20, 2023
- Enrollment
- 618
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CelgeneLead sponsor
- Bristol-Myers SquibbOfficial
- Bristol-Myers SquibbCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.